The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.
OBJECTIVE
The purpose of this study was to determine the correlations between inflammatory factors-including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin-and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT).


METHODS
Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013.


RESULTS
The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 × 10(9)/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively).


CONCLUSIONS
Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.
Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
Cheolsu
C
Kim
Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
Ho Sup
HS
Lee
Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Chang-Ki
CK
Min
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Je Jung
JJ
Lee
Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kihyun
K
Kim
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Dok Hyun
DH
Yoon
Department of Internal Medicine, National Cancer Center, Goyang, Korea.
Hyeon Seok
HS
Eom
Department of Internal Medicine, National Cancer Center, Goyang, Korea.
Hyewon
H
Lee
Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
Won Sik
WS
Lee
Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Ho-Jin
HJ
Shin
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Ji Hyun
JH
Lee
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Yong
Y
Park
Department of Hematology and Oncology, Ulsan University Hospital, Ulsan, Korea.
Jae-Cheol
JC
Jo
Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
Young Rok
YR
Do
Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.
Yeung-Chul
YC
Mun
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006785:Hospitals, University; D006801:Humans; D060828:Induction Chemotherapy; D018836:Inflammation Mediators / Q000097:blood*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D015999:Multivariate Analysis; D020360:Neoadjuvant Therapy; D016017:Odds Ratio; D016016:Proportional Hazards Models; D056910:Republic of Korea; D012189:Retrospective Studies; D012307:Risk Factors; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018836:Inflammation Mediators; D013792:Thalidomide
Inflammation; Multiple myeloma; Prognosis; Thalidomide